TED
Aug 02 2022
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
Read MoreCorneal Epithelial Defect
Aug 02 2022
A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Read MoreSIRIUS
Feb 08 2022
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene with Advanced Vision Loss (SIRIUS).
Read MoreCLN-0500
Aug 24 2021
A Randomized, Parallel-Arm, Active Control, Multicenter Study Assessing the Safety and Efficacy of Dextenza for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
Read MoreATMOSPHERE
Aug 24 2021
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Read MoreUNITY
Aug 24 2021
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
Read MorePEP
Aug 24 2021
Patient Experience and Preference (PEP) Study in nAMD and DME Sponsor: Hoffmann-La Roche Ltd
Read MoreMAC TEL
Dec 01 2020
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (Mac Tel) Sponsor: Neurotech Pharmaceuticals, Inc. clinicaltrials.gov
Read More